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Abstract
Objectives To determine the accuracy and assess the clinical
significance of surface-coil 1.5-T magnetic resonance imag-
ing (MRI) for the detection of locally advanced prostate
cancer (PCa).
Methods Between December 2007 and January 2010, we
examined 209 PCa patients (mean age062.5 years) who were
consecutively treated with robot-assisted laparoscopic prosta-
tectomy and prospectively staged by MRI. One hundred and
thirty-five patients (64.6 %) had locally advanced disease.
Conventional clinical tumour stage and MRI-assessed tumour
stage were compared with histopathological tumour stage
(pT). Sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV) and overall accuracy (OA)
were calculated using pT as the “gold standard”. Overstaged
and understaged cases at MRI were reviewed.
Results Sensitivity, specificity, PPV, NPV and OA for the
detection of locally advanced disease were 25.9, 95.9, 92.1,
41.2 and 50.5 % and 56.3, 82.2, 85.4, 50.4 and 65.4 % for
clinical staging and MRI, respectively. Among patients
understaged at MRI, the resection margins were free in
64.4 % of the cases (38/59).
Conclusions Although the accuracy was limited, the detec-
tion of locally advanced disease improved substantially when
MRI was added to routine clinical staging. The majority of the
understaged patients nevertheless achieved free margins.
When assessing the clinical significance of MRI staging the
extent of extraprostatic extension has to be considered.
Key Points
• MRI substantially improves detection of locally advanced
prostate cancer
• MRI has limited overall staging accuracy
• Most T3 cancers unrecognised at MRI still achieved free
resection margins
• Assessing the true clinical contribution of MRI remains
challenging
Keywords Prostate cancer . Neoplasm staging . Prostatic
neoplasm .Magnetic resonance imaging . Sensitivity and
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Abbreviations
DRE Digital rectal examination
EPE Extraprostatic extension
mrT MRI-assessed tumour stage
DW Diffusion-weighted
NPV Negative predictive value
OA Overall accuracy
PCa Prostate cancer
PPV Positive predictive value
PSA Prostate-specific antigen
RALP Robot-assisted laparoscopic radical prostatectomy
TRUS Transrectal ultrasound
Introduction
Reliable identification of locally advanced prostate cancer
(PCa) is regarded crucial for making decisions on treatments
[1]. Traditionally, clinical evaluation of the extent of PCa
has been based on prostate-specific antigen (PSA), digital
rectal examination (DRE), transrectal ultrasound (TRUS)
and biopsy results [1]. These clinical tools often underesti-
mate tumour extent and are not accurate enough to recog-
nise locally advanced disease [1–4]. For other pelvic
malignancies, in particular rectal cancer, magnetic reso-
nance imaging (MRI) is the “gold standard” for detecting
locally advanced disease and for treatment stratification [5].
MRI is increasingly being used and recommended for PCa
staging [6–11]. However, a wide range of sensitivities and
specificities for staging have been reported [8, 11]. The use
of endorectal phased-array coil has been shown to signifi-
cantly improve the specificity of extraprostatic extension
(EPE) detection, but not the sensitivity when compared with
pelvic phased-array coil with equal image resolution [12].
Furthermore, use of an endorectal coil is associated with
increased costs, reduced patient throughput and discomfort
to the patient. The performance of MRI is limited by the
facts that low-grade tumours are hardly distinguishable from
normal prostate tissue [11], that malignant glandular tissue
often is intermixed with benign prostate tissue [13, 14], and
that the typical spatial resolution does not allow for the
detection of sub-millimetre disease [15].
There is currently an ongoing debate regarding the clin-
ical usefulness of PCa staging by MRI [9, 11, 16, 17]. The
main benefit of MRI staging probably lies in the discovery
of clinically unrecognised, locally advanced cancer. Being a
third-line referral cancer hospital with a significant propor-
tion of patients with locally advanced disease, our study
population is in this sense appropriate [18] for the assess-
ment of the clinical usefulness of MRI staging.
In this study, we explored the performance of clinical
routine pelvic MRI using phased-array coil and a widely
applicable imaging protocol for the detection of locally
advanced PCa. Consecutive and prospectively performed
MRI and histopathology interpretations were compared
without re-assessments or patient exclusions to ensure that
the reported data truly reflected routine clinical practice. We
also sought to assess clinical significance by reviewing




Between December 2007 and January 2010, 209 PCa
patients with preoperative MRI performed in our hospital
who had been consecutively stratified for surgical treatment
were included. Patients considered for radical prostatectomy
had no evidence of skeletal metastases, either at skeletal
scintigraphy (PSA>10 ng/ml) or at MRI. Patients preopera-
tively treated with radiation therapy or androgen deprivation
were excluded. Clinical data, including T-stage (cT) deduced
from routine DRE and TRUS performed at referral hospitals
and histopathological T-stage (pT) are summarised in Ta-
ble 1. The regional ethics committee approved the study and
granted a waiver of informed consent for this single-
institutional retrospective study of prospectively recorded
data.
MRI
Median number of days between biopsy or TUR-P and MRI
was 89 days (range=14–1,621 days). All patients underwent
MRI using a 1.5-T Siemens ESPREE (Siemens, Erlangen,
Germany) magnet and phased-array coils. An endorectal coil
was not used. TheMRI sequences and imaging parameters are
summarised in Table 2. T-stage was deduced from two differ-
ent T2-weigthed (T2W) sequences: transversal 3D SPACE
with isotropic voxels of 1 mm and transversal 2D TSE with
a native in-plane resolution of 0.6 × 0.6 mm2 and slice thick-
ness of 3–4 mm. For some patients, additional coronal T2W
images were acquired. Diffusion-weighted (DW) MRI of the
prostate and seminal vesicles, along with the T2W morpho-
logical images, were used for detecting tumours and assessing
their extent. DW MRI with multiple b values (50-300-500-
1,000 mm2/s, 0-50-300-500-2,000 mm2/s or 50-500-1,000-
1,500 mm2/s) and voxels of 2 × 2 × 4 mm3 were applied for
diffusion quantification (apparent diffusion coefficient, ADC).
For most patients, the protocol also included a heavily DW
(b02,000 mm2/s) sequence with larger voxels (3 × 3 × 6mm3)
for qualitatively assessing tumour localisation and extent.
Coronal 3D SPACE T1-weighted MR images with isotropic
voxels of 1.1 mm covering the whole pelvis and lower abdo-
men were acquired. Peristalsis was suppressed by intravenous
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administration of 1 mg butyl scopolamine (Buscopan®; Boeh-
ringer Ingelheim, Germany) and intramuscular administration
of 1 mg glucagon (Novo Nordisk, Bagsværd, Denmark).
The MR images were read by one of two experienced
radiologists independently (K.H.H. and K.K). At the start of
the study the radiologists (K.H.H. and K.K.) had 3 years of
prostate MRI experience with approximately 300 and 100
examinations per year, respectively. Tumour stage was clas-
sified according to the 5th edition TNM classification [19].
The biopsy results were available for the radiologists when
interpreting the MR images. Tumour in the prostate was
predicted by low signal intensity on T2W and T1W (no
haemorrhage) images and low ADC, with a correspondingly
high signal intensity on heavily DW images (b≥1,000) [9].
The criteria used for interpreting stage T3a were, in the
presence of tumour, capsular bulging, stranding into the
periprostatic fatty tissue or asymmetry of the nevrovascular
bundle [20, 21]. Thickening of the prostate capsule without
stranding or bulging beyond the confines of the prostate was
staged as T2. The criteria for stage T3b, invasion of the
seminal vesicles, were low signal intensity on T2W and
T1W (no haemorrhage) images with a correspondingly high
signal intensity on heavily DW images. Stage T4 was noted if
the tumour extended into the bladder neck. In case of uncer-
tainty, it was agreed that tumours should be downstaged.
MRI-assessed T-stage (mrT) data are summarised in
Table 1. For ten patients, no tumour could be identified at
MRI (mrT0). Movement and image artefacts made it impossi-
ble to assess tumour stages in two patients (mrTx). No patients
were excluded from the analyses, either mrT0 or mrTx.
Robot-assisted laparoscopic prostatectomy
A three-armed robotic DaVinci® system (Intuitive Sur-
gical, Sunnyvale, CA, USA) was used to perform robot-
assisted laparoscopic radical prostatectomy (RALP). The
operative positioning was in a steep Trendelenburg po-
sition (45º), and the surgical approach was based mainly
on the Vattikutti Institute technique [22]. The median
number of days between MRI and RALP was 81
(range00–358). Where MRI showed an EPE, a locally
extended excision was performed.
Histopathological assessment of tumour stage
The specimens were coated with three different inks and
fixed in 10 % buffered formaldehyde for at least 2 days.
Grossing was performed according to a standardised proto-
col where total prostate with seminal vesicles was embed-
ded. [23, 24]. The apex and base of the prostate was cut by
the cone method as sagittal sections. The remaining body of
the prostate was sectioned serially at 3–4 mm intervals in the
transverse plane and prepared as whole-mount sections. The
understaged specimens were examined by two experienced
uropathologists (A.K.L. and L.V.). The extent of EPE was
classified as focal or established using the method described
by Sung and co-workers [25] using a cut-off at 1 mm for the
radial distance of EPE. Histopathological staging was per-
formed according to the 5th edition TNM classification [19]
and the modified Gleason score system was used for assess-
ing tumour aggressiveness [26].
Histopathological T-stage data are summarised in Table 1.
For one patient, intraprostatic incision was present, hence
the presence or absence of EPE could not be reliably







< 20 153 (73.2 %)
≥ 20 and≤50 3 (22.0 %)
> 50 10 (4.8 %)
Gleason score from core biopsies
5–6 51 (24.4 %)
7a (3+4) 60 (28.7 %)
7b (4+3) 49 (23.4 %)





T1c 96 (45.9 %)
T2a/T2b 53 (25.4 %)
T2c 22 (10.5 %)
T3 38 (18.2 %)
MR T-stage
T0 10 (4.8 %)
T2a/b 52 (24.9 %)
T2c 55 (26.3 %)
T3a 74 (35.4 %)
T3b 13 (6.2 %)
T4 3 (1.4 %)
Tx 2 (1.0 %)
Histopathological T-stage
T2a 11 (5.3 %)
T2c 62 (29.7 %)
T3a 96 (45.9 %)
T3b 34 (16.3 %)
T4 5 (2.4 %)
Tx 1 (0.4 %)
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assessed, and this patient was excluded from the analyses
(pTx). Thus, the number of patients eligible for an assess-
ment of MR performance was 208.
Data analysis
The histopathological tumour stage was compared with cT
and mrT by using descriptive statistics. The comparison
between MRI and histopathology was performed on a per
patient basis. Diagnostic accuracy for assessing locally ad-
vanced disease was obtained by calculating sensitivity, spec-
ificity, positive predictive value (PPV), negative predictive
value (NPV) and overall accuracy (OA). In the overstaged
cases, the MRI examinations and reports were reviewed. In
the understaged cases, the radial extent of EPE was quanti-
fied in the prostatectomy specimens if the surgical margin
was positive.
Results
T-stage by DRE and TRUS
Staging accuracy is summarised in Fig. 1. A total of 35 out
of 135 patients (25.9 %) with a histologically verified EPE
were clinically recognised as T3. Specificity, PPV, NPV and
OA for identifying locally advanced disease were 95.9,
92.1, 41.2 and 50.5 %, respectively. Locally advanced dis-
ease was found in 49 out of 96 patients (51.0 %) with
clinical T1c. For patients with cT2 tumour, 51 of 74 patients
(68.9 %) had more advanced disease than clinically
anticipated.
T-stage by MRI
Staging accuracy is summarised in Fig. 2. MRI detected
EPE in 76 of 135 patients (56.3 %) with locally advanced
disease. Specificity, PPV, NPV and OA for the detection of
locally advanced disease were 82.2, 85.4, 50.4 and 65.4 %,
respectively.
Table 2 MRI protocol and sequence parameters
MRI parameter MRI sequence
T2W 3D SPACE T2W TSE T1W TSE DW (ADC calculation) DW
Slice orientation Transversal Transversal Coronal Transversal Transversal
Echo time (ms) 104–120 74–88 12 78–106 83
Repetition time (ms) 1,500–2,000 3,000–5,840 500–643 3,500–4,900 3,000
Slice thickness (mm) 1 2.5–4 5 3–4 6
Slice gap (mm) 0 0–1 1 0.75–1 1
Number of acquisitions 1 2–8 1 7–9 12
Field of view (mm×mm) 360×360 or 448×448 200×200 340×340 260×260 or 384×288 260×260
Pixel size (mm×mm) 1.0×1.0 0.6×0.6 0.9×0.9 2.0×2.0 3.0×3.0
Turbo factor 21–41 15 5




MRI magnetic resonance imaging, TSE turbo spin echo, DW diffusion-weighted, ADC apparent diffusion coefficient, SPACE sampling perfection

































Fig. 1 Accuracy of digital rectal exploration (DRE) and transrectal
ultrasound (TRUS) for detection of extraprostatic tumour extension
(EPE)
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MRI overstaging
In 13 cases (9.6 %) MRI indicated locally advanced disease
that was not confirmed by histopathology (Fig. 2). In all
these cases uncertainty regarding the presence or absence of
EPE was noted in the MRI report. All patients had small
glands and none showed post-biopsy haemorrhage.
MRI understaging
Fifty-nine patients with locally advanced disease were inter-
preted as having organ-confined disease at MRI (Fig. 2).
Thirty-eight of these patients had a free resection margin
(Fig. 3). The re-evaluation of the remaining 21 cases revealed
four patients with focal EPE (< 1 mm) (Fig. 4), whereas
17 patients had established EPE exceeding 1 mm, (mean0
1.5 mm, range01–6 mm) (Fig. 5).
Cumulative T3 detection performance
Cumulative performance for the detection of locally ad-
vanced PCa is summarised in Fig. 6. The detection rate from
routine DRE and TRUS was 25.9 %. When preoperative
MRI was added, the detection rate increased by 30.4 % (to
56.3 %). Out of all the patients who were understaged at
MRI, 38 achieved a free resection margin (28.1 %), whereas
21 (15.6 %) did not.
Discussion
This report shows that although limited in overall accuracy,
the detection of locally advanced disease improved substan-
tially when phased array 1.5-T MRI was added to clinical
staging by routine DRE and TRUS. Furthermore, for most
patients the misrecognition of EPE did not lead to a com-
promised surgical outcome.
The accuracy of the detection of locally advanced
PCa in our study (65.4 %) was within the range, but
at the lower end of previously published studies (59.4–
85.9 %) [12, 27–31]. The wide range of reported accu-
racy levels reflects differences in patient populations,
histopathological interpretations, evaluation methods,
MR technology and reader experience; thus, compari-
sons of reported results and assessments of clinical
significance are challenging. Even with a MRI protocol
representing minimal technical requirements [9, 16] and
a limited overall accuracy, the clinical significance of
MRI staging in our study was evident, as EPE leading
to a positive margin was overlooked in only 21 cases
(15.6 %).
Patient populations influence staging accuracy, as a
high rate of organ-confined disease may obscure a
poor detection of locally advanced disease, and small
study populations may result in higher staging perfor-
mance [18]. Our study population was relatively large
(n0208) and consisted of 64.9 % with stage pT3-
disease. Furthermore, we did not exclude examinations
with unsatisfactory image qualities; hence, our results
reflected routine radiological practice. A limitation to
our study is the lack of sector-based comparison be-
tween MRI and histopathology. Neither the side nor
the level of EPE was consistently reported in the pro-
spectively recorded data.
In 2009 the International Society of Urological Pa-

































Fig. 2 Accuracy of routine pelvic MRI using phased-array coil for
detection of extraprostatic tumour extension (EPE)












Fig. 3 Exploration of the 59 cases interpreted as organ confined
disease at MRI but with locally advanced disease at pathology
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stratified into focal (Fig. 4) or minimal, or established
(Fig. 5) or extensive [32]. However, no consensus has
been reached regarding the criteria of focal versus
established EPE [1, 32, 33]. ISUP also reported con-
siderable inconsistencies in the interpretation of EPE
status in equivocal specimens. This inconsistency inev-
itably will influence the level of MRI accuracy as
histopathological evaluation is considered the “gold
Fig. 4 Focal extraprostatic
extension. a T2W MRI with a
heavily DW image of the
prostate overlaid (in colour). b
T2W close-up of the prostate. c
Corresponding whole-mount
section with a 1 mm2 grid
overlay. d Close-up microscop-
ic views; 40× magnification
shows tumour islet (black ar-
row) representing focal extrap-
rostatic extension of less than
1 mm radial in length, which
was unrecognised and not
clearly demonstrated (white ar-
row, b) at MRI
Fig. 5 Established
extraprostatic extension. a T2W
MRI with a heavily DW image
of the prostate overlaid (in
colour). b T2W close-up of the
prostate. c Corresponding
whole-mount section with a
1 mm2 grid overlay. d Close-up
microscopic view. The dashed
line represents the boundary of
the prostate and the black arrow
indicates the extraprostatic ex-
tension of 2–3 mm in radial
length, which was clearly dem-
onstrated (white arrow, b) and
correctly staged at MRI
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standard”. In our study, a striking 64.4 % of the unrec-
ognised T3 cases at MRI had free margins. When
considering that extended surgery was not performed
due to preoperative interpretation of organ-confined
disease, free margins indicate that the extension of
EPE was minimal (focal EPE). Consequently, by using
established EPE [32, 33] as the histopathological crite-
rion for clinically significant, locally advanced disease,
MRI accuracy may improve.
Image resolution is critical for the visualisation of
EPE. According to the Nyquist theorem, anatomical
structures must be twice the sampling size (pixel) in
order to be detected. The resolution used in our MR
sequences does not allow for the reliable depiction of
EPE with an extent less than approximately 1 mm.
Millimetre resolution is also recommended for MR
staging in other pelvic malignancies [5, 34, 35]. A
radial extent of EPE that exceeds 1 mm has recently
been reported to predict recurrence [36, 37]. Improved
resolution using endorectal coil [12] and higher field
strengths have been shown to enable the detection of
EPE of 0.5 mm [12, 15]. However, very small voxels
does not necessarily translate into improved detection
of focal EPE, as minor involuntary movement of the
prostate will induce partial volume effects. Further-
more, depicting EPE of less than 1 mm will not nec-
essarily improve surgical outcome. Due to limited
spatial resolution, dynamic contrast-enhanced MRI
would probably not improve the detection of focal
EPE [28].
In the case of equivocal EPE status at MRI, we
agreed to downstage, and thus the overstaging rate
was low (9.6 %). However, this practice led to under-
staging. Tumour admixed with extraprostatic fat or
bladder musculature is characteristic of EPE, and micro-
scopic tumour foci and focal EPE (< 1 mm) will not be
detectable at MRI (Fig. 4). As a result, understaging is
unavoidable. Therefore, if MRI is to be a useful
decision-making tool for urologists, overstaging must
be minimised. By using clearly visualised EPE as an
MRI criterion for T3 disease, a high PPV (85.4 %) was
achieved. The risk associated with systematic downstag-
ing is that surgeons may wrongly assume that the nerve-
sparing approach is safe.
When attempting to contextualise our MR findings,
we realised that concerns related to pathology and
surgery had to be considered. As the majority of
patients with unrecognised locally advanced disease
achieved free resection margin, the clinical significance
of MRI is obviously not reflected solely by T-stage
accuracy. In the light of recent reports that indicate
the prognostic significance of radial EPE quantification
[36, 37] and the limited ability of MRI to detect focal
EPE, stratification of EPE as focal or established is of
importance when assessing the clinical significance of
MRI. If the clinical significance of MRI is assessed in
terms of resection margin status, consideration must be
given to both the extent of EPE and the surgical plane
of dissection (preserving function versus ensuring free
margin). Based on the results and limitations of our
study, we are currently investigating in a prospective
study (ClinicalTrials NCT01464216) the relationship
between multiparametric MRI with increased spatial
resolution, the radial extent of EPE at pathology, sur-
gical techniques, resection margin status and long-term
follow-ups.
In conclusion, although the detection accuracy was
limited, MRI substantially improved the detection of
locally advanced disease when added to conventional
staging by routine DRE and TRUS. Strict MRI criteria
for EPE ensured minimal overstaging, but induced
understaging. Free resection margins were achieved for
the majority of patients were MRI failed to recognise
EPE. This indicates that the clinical significance of T-
staging by MRI is not fully reflected by the ability to
detect EPE per se. By stratifying the extent of EPE into
focal or established, the staging accuracy is likely to
increase as will the clinical significance of MRI as a
tool for treatment planning.
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Fig. 6 Cumulative performance for detection of non-organ confined
prostate cancer. The bar represents all 135 patients with extraprostatic
extension (EPE). Separate percentages are given for digital rectal
exploration (DRE) and transrectal ultrasound (TRUS) combined, for
magnetic resonance imaging (MRI), and for those with unrecognised
EPE with negative and positive resection margins
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